Sinomab Announces News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Hong kongWilla xueSinomab bioscience limited stock codeSignificant new drugs development of the twelfthAsia corporate news networkSinomab bioscienceNational medical products administration of chinaDrug administrationSinomab announcesDomestic clinicalHong kong basedMab bioscience limitedStock codeInvestigational new drugNational medical products administrationIdiopathic pulmonary fibrosis

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesWilla xueNational medical products administration of chinaSignificant new drugs development of the twelfthDrug administrationAsia corporate news networkSinomab bioscience limited stock codeSinomab bioscienceSinomab announcesDomestic clinical trialsBlue oceanHong kong basedMab bioscience limitedStock codeInvestigational new drug

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Sinomab bioscienceSignificant new drugs development of the twelfthNational medical products administration of chinaAsia corporate news networkSinomab bioscience limitedSinomab announcesMab bioscience limitedHong kong basedInvestigational new drugDrug evaluationNational medical products administrationExecutive directorChief executive officerFlagship productSignificant new drugs developmentTwelfth five year plan period

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Sinomab bioscienceSignificant new drugs development of the twelfthAsia corporate news networkSinomab bioscience limitedSinomab announcesFlagship productMab bioscience limitedHong kong basedExecutive directorChief executive officerSignificant new drugs developmentTwelfth five year plan periodThirteenth five year planAsia corporate news